Drugs / C-CAR039
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05149391 | Jul 2021 → Jan 2024 | B-cell non-Hodgkin lymphoma | Peking University | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-16 | Shanghai AbelZeta Ltd. | AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma abelzeta.com ↗ |
| 2025-06-16 | Shanghai AbelZeta Ltd. | AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025 abelzeta.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C-CAR039 | “C-CAR039” NCT05149391 ↗ |
| Modality | Cell therapy | “Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells” NCT05149391 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT05149391 ↗ |
| Target | CD19 | “CD19/CD20-directed Chimeric Antigen Receptor T Cells” NCT05149391 ↗ |